1. Home
  2. KRYS vs GVA Comparison

KRYS vs GVA Comparison

Compare KRYS & GVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • KRYS
  • GVA
  • Stock Information
  • Founded
  • KRYS 2015
  • GVA 1922
  • Country
  • KRYS United States
  • GVA United States
  • Employees
  • KRYS N/A
  • GVA N/A
  • Industry
  • KRYS Biotechnology: Biological Products (No Diagnostic Substances)
  • GVA Military/Government/Technical
  • Sector
  • KRYS Health Care
  • GVA Industrials
  • Exchange
  • KRYS Nasdaq
  • GVA Nasdaq
  • Market Cap
  • KRYS 4.7B
  • GVA 4.5B
  • IPO Year
  • KRYS 2017
  • GVA 1990
  • Fundamental
  • Price
  • KRYS $196.65
  • GVA $98.51
  • Analyst Decision
  • KRYS Strong Buy
  • GVA Strong Sell
  • Analyst Count
  • KRYS 9
  • GVA 1
  • Target Price
  • KRYS $214.22
  • GVA $76.00
  • AVG Volume (30 Days)
  • KRYS 316.5K
  • GVA 533.9K
  • Earning Date
  • KRYS 11-03-2025
  • GVA 11-06-2025
  • Dividend Yield
  • KRYS N/A
  • GVA 0.53%
  • EPS Growth
  • KRYS 275.72
  • GVA 64.91
  • EPS
  • KRYS 6.66
  • GVA 3.67
  • Revenue
  • KRYS $373,164,000.00
  • GVA $4,236,312,000.00
  • Revenue This Year
  • KRYS $34.33
  • GVA $11.99
  • Revenue Next Year
  • KRYS $48.04
  • GVA $9.45
  • P/E Ratio
  • KRYS $29.71
  • GVA $26.86
  • Revenue Growth
  • KRYS 54.51
  • GVA 6.87
  • 52 Week Low
  • KRYS $122.80
  • GVA $69.08
  • 52 Week High
  • KRYS $212.98
  • GVA $112.16
  • Technical
  • Relative Strength Index (RSI)
  • KRYS 59.19
  • GVA 25.53
  • Support Level
  • KRYS $194.92
  • GVA $100.00
  • Resistance Level
  • KRYS $212.98
  • GVA $104.92
  • Average True Range (ATR)
  • KRYS 8.35
  • GVA 2.58
  • MACD
  • KRYS -0.17
  • GVA -0.46
  • Stochastic Oscillator
  • KRYS 42.14
  • GVA 13.38

About KRYS Krystal Biotech Inc.

Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on the development of easy-to-use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future. The company has one operating segment, which is the business of developing and commercializing pharmaceutical products.

About GVA Granite Construction Incorporated

Granite Construction Inc engages in the construction and development of various infrastructure projects on behalf of public and private clients in the United States. It focuses on heavy civil infrastructure projects, including roads, highways, transit facilities, airports, bridges, and other infrastructure projects. In addition, the company performs site preparation and infrastructure services for residential development, energy development, and other facilities. The majority of revenue is derived from the company's Construction operating segment, with the remainder derived from its Materials segment.

Share on Social Networks: